FVFatima Valero‐Sempere

Fatima Valero‐Sempere

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Fatima Valero‐Sempere has a total of 19 co-authors. Here are the top co-authors by number of shared publications:

  • Esperanza Merino

    Unit of infectious Diseases Dr. Balmis General University Hospital - Alicante Institute of Health and Biomedical Research (ISABIAL), Avda Pintor Baeza, 12, Alicante 03010, Spain; Clinical Medicine Department, Miguel Hernández University, Carretera N-332, s/n , Sant Joan d'Alacant, Alicante 03550, Spain

    3 shared publications
  • Jos&Eacute Manuel Ramos

    Clinical Medicine Department, Miguel Hernández University of Elche, 03550 Alicante, Spain

    3 shared publications
  • Héctor Pinargote-Celorio

    Unit of infectious Diseases Dr. Balmis General University Hospital - Alicante Institute of Health and Biomedical Research (ISABIAL), Avda Pintor Baeza, 12, Alicante 03010, Spain

    2 shared publications
  • Juan Carlos Rodríguez

    Clinical Medicine Department, Miguel Hernández University, Carretera N-332, s/n , Sant Joan d'Alacant, Alicante 03550, Spain; Microbiology Service, Dr. Balmis General University Hospital - Alicante Institute of Health and Biomedical Research (ISABIAL), Avda Pintor Baeza, 12, Alicante 03010, Spain

    2 shared publications
  • Rosario Sanchez‐Martinez

    Internal Medicine Department Dr. Balmis University General Hospital and Alicante Institute for Health and Biomedical Research (ISABIAL) Alicante Spain

    2 shared publications
  • Silvia Otero-Rodriguez

    Infectious Diseases Unit, Doctor Balmis University General Hospital, 03010 Alicante, Spain

    2 shared publications

Latest Publications

  • Open Access

    In‐Hospital Death and Risk Factors in Adults With Respiratory Syncytial Virus in Spain (2016–2023). A Cross‐Sectional Study With Focus on Older Patients

    by Fatima Valero‐Sempere, Mayarí Tortosa‐González, Silvia Otero‐Rodriguez, Maripaz Ventero, Juan Carlos Rodriguez‐Diaz, Pilar Casasnovas, Hector Pinargote‐Celorio, Rosario Sanchez‐Martinez, Esperanza Merino, Jose Manuel Ramos‐Rincon

    Background and Aims: Respiratory syncytial virus (RSV) mortality varies across different populations. This study aims to assess RSV mortality in hospitalized adults (≥ 15 years) and identify key risk factors according to age. Methods: This was a retrospective, single‐center study conducted in Alicante (Spain), including patients hospitalized for PCR‐confirmed RSV infection between 2016 and 2023. Risk factors for death were assessed using multivariable logistic regression. Results: Of 367 patients admitted for RSV, 24 died (6.5%). Mortality was higher in very old adults (≥ 80 years, 8.9%) than in those aged under 80 years (4.8%). Significant risk factors were glomerular filtration rate (GFR) less than 38 mL/min/m 2 (adjusted odds ratio [aOR] 3.15, 95% confidence interval [CI] 1.16–8.56), use of high‐flow nasal cannula (aOR 3.67, 95% CI 1.15–11.74), and metastatic cancer (aOR 10.01, 95% CI 1.28–78.55). In the group ≤ 79 years ( n = 210), risk factors were non‐invasive mechanical ventilation (aOR 26.07 95% CI 2.01–338) and C‐reactive protein levels over 11 mg/dL (aOR 12.48, 95% CI 1.14–136). In the patients ≥ 80 years ( n = 157; 42.8%), low GFR was associated with higher mortality (aOR 4.53, 95% CI 1.36–15.04). Conclusion: RSV deaths increase with age. In‐hospital mortality was associated with non‐invasive mechanical ventilation and C‐reactive protein levels and in patients under 80, and low GFR in older patients.

  • Open Access

    In‐Hospital Death and Risk Factors in Adults With Influenza in Spain (2016–2022): A Cross‐Sectional Study With Focus on Older Patients

    by Jose‐Manuel Ramos‐Rincon, Hector Pinargote‐Celorio, Rosario Sanchez‐Martinez, Juan‐Carlos Rodríguez‐Diaz, Silvia Otero, Fatima Valero‐Sempere, Diego Torrús, Beatriz Valero‐Novella, Geronima Riera, Vicente Boix, et al.

    Background and Aims: Influenza mortality rates varying across different populations. This study aims to assess influenza lethality in hospitalized adults (≥ 15 years) and identify key risk factors according to age.Methods: We designed a retrospective study at Dr. Balmis General University Hospital (Alicante, Spain), including patients hospitalized for influenza from 2016 to 2022. In‐hospital death was expressed as the case fatality rate (CFR). Variables yielding a p value under 0.1 on univariable analysis were included in the multivariable logistic regression model to identify risk factors for lethality.Results: Of 1613 patients admitted for influenza (incidence 86 per 10,000 admissions), 96 died (CFR 5.95%). Lethality increased with age, reaching 8.4% in patients aged 80–89 years and 19.5% in those over 90. In all of the cohort, risk factors were age, dementia, respiratory failure, influenza pneumonia, and sepsis, while treatment with oseltamivir acted as a protective factor. In patients < 80 years of age, risk factors were neoplasia, respiratory failure, and influenza pneumonia, whereas oseltamivir treatment was a protective factor. In patients 80 years (n = 554; 34.3%), the risk of mortality increased with age, dementia, respiratory failure, noninfluenza pneumonia, and sepsis.Conclusion: Influenza deaths increase with age; this relationship is accentuated in people aged 80 or older. Respiratory failure was the main risk factor in all patients hospitalized for influenza. Treatment with oseltamivir protected patients (especially those < 80 years) against deaths. Patients < 80 years‐old carried a higher risk of death if they had a neoplasia, whereas in ≥ 80 patients, the risk was associated with dementia and noninfluenza pneumonia.


  • Top Cited Papers
    Open Access

    Association between Clinical Frailty Scale (CFS) and clinical presentation and outcomes in older inpatients with COVID-19

    by Ana Martí-Pastor, Oscar Moreno-Perez, Esther Lobato-Martínez, Fatima Valero-Sempere, Antonio Amo-Lozano, María-Ángeles Martínez-García, Esperanza Merino, Rosario Sanchez-Martinez, Jose-Manuel Ramos-Rincon

    Background: Frailty is a physiological condition characterized by a decreased reserve to stressors. In patients with COVID-19, frailty is a risk factor for in-hospital mortality. The aim of this study was to assess the relationship between clinical presentation, analytical and radiological parameters at admission, and clinical outcomes according to frailty, as defined by the Clinical Frailty Scale (CFS), in old people hospitalized with COVID-19. Materials and methods: This retrospective cohort study included people aged 65 years and older and admitted with community-acquired COVID-19 from 3 March 2020 to 31 April 2021. Patients were categorized using the CFS. Primary outcomes were symptoms of COVID-19 prior to admission, mortality, readmission, admission in intensive care unit (ICU), and need for invasive mechanical ventilation. Analysis of clinical symptoms, clinical outcomes, and CFS was performed using multivariable logistic regression, and results were expressed as odds ratios (ORs) and 95% confidence intervals (CIs). Results: Of the 785 included patients, 326 (41.5%, 95% CI 38.1%–45.0%) were defined as frail (CFS ≥ 5 points): 208 (26.5%, 95% CI 23.5%–29.7%) presented mild-moderate frailty (CFS 5–6 points) and 118 (15.0%, 95% CI 12.7%–17.7%), severe frailty (7–9 points). After adjusting for epidemiological variables (age, gender, residence in a nursing home, and Charlson comorbidity index), frail patients were significantly less likely to present dry cough (OR 0.58, 95% CI 0.40–0.83), myalgia-arthralgia (OR 0.46, 95% CI 0.29–0.75), and anosmia-dysgeusia (OR 0.46, 95% CI 0.23-0.94). Confusion was more common in severely frail patients (OR 3.14; 95% CI 1.64-5.97). After adjusting for epidemiological variables, the risk of in-hospital mortality was higher in frail patients (OR 2.79, 95% CI 1.79-4.25), including both those with mild-moderate frailty (OR 1.98, 95% CI 1.23-3.19) and severe frailty (OR 5.44, 95% CI 3.14-9.42). Readmission was higher in frail patients (OR 2.11, 95% CI 1.07–4.16), but only in mild-moderate frailty (OR 2.35, 95% CI 1.17–4.75).. Conclusion: Frail patients presented atypical symptoms (less dry cough, myalgia-arthralgia, and anosmia-dysgeusia, and more confusion). Frailty was an independent predictor for death, regardless of severity, and mild-moderate frailty was associated with readmission.